Projects

International

• COMPREHENSIVE CANCER INFRASTRUCTURES 4 EUROPE
  Program: Horizon Europe
  Duration: 1. 5. 2023 – 30. 4. 2026

National

• Study of Gut Microbiome Modulation by Butyrate Administration in Patients with Hematologic Malignancies Undergoing Hematopoietic Stem Cell Transplantation or CAR-T Cell Therapy.
  Program: VEGA
  Duration: 1. 1. 2026 – 31. 12. 2029

• Identification of new immune related therapeutic targets in treatment refractory testicular germ cell tumors
  Program: SRDA
  Duration: 1. 9. 2025 – 30. 6. 2029

• Impact of the gut microbiome on the treatment and prognosis of patients with testicular germ cell tumors.
  Program: VEGA
  Duration: 1. 1. 2024 – 31. 12. 2027

• The emerging role of the microbiome in hematologic cancer patients receiving high-dose chemotherapy with hematopoietic stem cell transplantation.
  Program: VEGA
  Duration: 1. 1. 2022 – 31. 12. 2025

• Regulation of epithelial-mesenchymal transition by microRNA and promoter methylation in invasive breast cancer
  Program: VEGA
  Duration: 1. 1. 2019 – 31. 12. 2022

• The dynamics of inflammation-induced epigenetic changes during epithelial-to-mesenchymal transition and their role in human pancreatic ductal adenocarcinoma progression
  Program: VEGA
  Duration: 1. 1. 2018 – 31. 12. 2021

• Expression analysis of miRNA genes regulating the biology of cancer stem cells in breast cancer patients
  Program: VEGA
  Duration: 1. 1. 2017 – 31. 12. 2020

• The study of gut microbiome in patients with colorectal cancer
  Program: VEGA
  Duration: 1. 1. 2017 – 31. 12. 2020

• The study of APC gene and its expression in vitro
  Program: VEGA
  Duration: 1. 1. 2013 – 31. 12. 2016

• The role of bacteria in a process of carcinogenesis and syndrome of acquired immunodeficiency
  Program: SRDA
  Duration: 1. 7. 2012 – 31. 12. 2015